{"id":32309,"date":"2026-03-21T23:20:05","date_gmt":"2026-03-21T17:50:05","guid":{"rendered":"https:\/\/niir.org\/blog\/?p=32309"},"modified":"2026-04-11T18:14:14","modified_gmt":"2026-04-11T12:44:14","slug":"semaglutide-patent-expiry-india","status":"publish","type":"post","link":"https:\/\/www.niir.org\/blog\/semaglutide-patent-expiry-india\/","title":{"rendered":"Semaglutide Patent Expiry in India: \u20b95000 Crore Pharma Business Opportunity"},"content":{"rendered":"

Introduction: semaglutide patent expiry India<\/strong><\/p>\n

The expiration of the patent for Semaglutide in March 2026 has given rise to one of the biggest business opportunities in the Indian pharmaceutical sector for the last few years. The diabetes and obesity treatment world has experienced a major breakthrough with this molecule which people now recognize from its use in Ozempic and Wegovy products.<\/p>\n

For years, these drugs were costly because they were protected by patents held by global pharmaceutical innovators such as Novo Nordisk. With expiration of the patent in India now, domestic pharmaceutical manufacturers are now quickly coming to the market with affordable versions of it. This change not only has enhanced patient access to advanced therapies, but also paved the way for a new industrial ecosystem from manufacturing, logistics, medical devices, and exports.<\/p>\n

Industry analysts estimate that the Indian semaglutide market may rise to around 5,000 crores of rupees every year in the next 12 to 18 months. For entrepreneurs, investors and pharmaceutical professionals, this is a rare window of opportunity to enter a fast-growing healthcare sector.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n